Trial · NCT07879508
Blast-related Regional Anaesthesia and Peripheral nerVe Injury Evaluation
NCT07879508, Not applicable, Not yet recruiting, Ukrainian Society of Regional Anesthesia and Pain Therapy
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Blast-related Regional Anaesthesia and Peripheral nerVe Injury Evaluation. Trials, record NCT07879508. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07879508
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Blast-related Regional Anaesthesia and Peripheral nerVe Injury Evaluation
- NCT number
- NCT07879508
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 150 participants, estimated
- Lead sponsor
- Ukrainian Society of Regional Anesthesia and Pain Therapy
- Conditions
- Nerve Block, Nerve Blocks, Nerve Injury, Blast Injury, Combat Related Symptoms, Combat Trauma
- Interventions
- Standardized Multimodal Analgesia, Ultrasound-Guided Regional Anaesthesia
- First posted
- 2026-10-19
- Last updated
- 2026-10-19
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | New or Worsened Peripheral Nerve Deficit at 30 Days | 30 days after randomization | Peripheral nerve function will be assessed before randomization and at 30 days using a standardized bilateral neurological examination. Motor function will be graded with the Medical Research Council (MRC) scale (0-5) in muscle groups corresponding to the injured limb and relevant peripheral nerves. Sensory function will be mapped in predefined nerve territories using light touch and pinprick and graded as 0 = absent, 1 = reduced/abnormal, or 2 = normal. New neuropathic symptoms, including numbness, tingling, burning pain, or allodynia, will also be documented. A primary outcome event is defined as a new sensory or motor deficit, or worsening of a pre-existing deficit, compared with the pre-randomization examination. Persistent, severe, progressive, or anatomically unexplained deficits will undergo neurological consultation and, when clinically indicated, nerve conduction studies/electromyography and/or ultrasound or MRI. Final outcome classification will be made by independent assess |
| Secondary | Acute Pain Intensity | Baseline; 6, 24, 48, and 72 hours after randomization | Pain at rest and during movement measured on an 11-point Numeric Rating Scale (NRS; 0=no pain, 10=worst imaginable pain). |
| Secondary | Persistent Peripheral Nerve Deficit | 90 days and 6 months after randomization | Persistent peripheral nerve deficit will be measured by comparing standardized neurological examinations at 90 days and 6 months with the pre-randomization examination. Motor function will be assessed using the Medical Research Council (MRC) scale (0-5) in relevant muscle groups. Sensory function will be assessed in predefined peripheral nerve territories using light touch and pinprick and graded as 0 = absent, 1 = reduced/abnormal, or 2 = normal. A persistent deficit is defined as a sensory and/or motor abnormality that is new or worse than baseline and remains present at the follow-up assessment. Participants with a persistent, progressive, or clinically significant deficit will undergo neurological review and, when clinically indicated, nerve conduction studies/electromyography and/or ultrasound or MRI. |
| Secondary | Neuropathic Pain | 30 days, 90 days, and 6 months after randomization | Neuropathic pain will be assessed using the Douleur Neuropathique 4 (DN4) questionnaire. The DN4 score ranges from 0 to 10; a score of 4 or higher will be considered consistent with neuropathic pain. Pain intensity will be measured using an 11-point Numeric Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain) at rest and during movement. The location and distribution of pain will be recorded and compared with the anatomical distribution of the traumatic injury and any neurological deficit. |
| Secondary | Limb Function | 30 days, 90 days, and 6 months after randomization | Limb function and pain-related functional interference will be assessed using the Brief Pain Inventory-Interference subscale (BPI-I). Participants rate how much pain interferes with seven domains: general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Each item is scored from 0 to 10, where 0 indicates no interference and 10 indicates complete interference. The mean BPI-I score will be calculated when sufficient items are completed; higher scores indicate greater pain-related functional limitation. For participants with lower-limb injury, mobility status and ability to bear weight or use a prosthesis, where applicable, will also be recorded. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07879508
GET https://conductscience.org/api/trials/v1/NCT07879508/registered